Catherine E. Storrer

1.4k total citations
26 papers, 1.2k citations indexed

About

Catherine E. Storrer is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Catherine E. Storrer has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 16 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Catherine E. Storrer's work include Immunotherapy and Immune Responses (22 papers), vaccines and immunoinformatics approaches (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Catherine E. Storrer is often cited by papers focused on Immunotherapy and Immune Responses (22 papers), vaccines and immunoinformatics approaches (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Catherine E. Storrer collaborates with scholars based in United States, United Kingdom and Switzerland. Catherine E. Storrer's co-authors include George E. Peoples, Sathibalan Ponniah, Craig D. Shriver, Jennifer M. Gurney, Matthew T. Hueman, Constantin G. Ioannides, Elizabeth A. Mittendorf, Christine M. Fisher, Michael Woll and Zia A. Dehqanzada and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Catherine E. Storrer

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Catherine E. Storrer United States 16 939 627 414 382 61 26 1.2k
Katharine M. Bendt United States 13 417 0.4× 475 0.8× 191 0.5× 517 1.4× 59 1.0× 15 1000
M.J. Troychak United States 10 786 0.8× 423 0.7× 123 0.3× 439 1.1× 69 1.1× 13 1.0k
Gijs Verheijden Netherlands 11 262 0.3× 367 0.6× 385 0.9× 313 0.8× 28 0.5× 21 847
Louise W. Treffers Netherlands 9 449 0.5× 198 0.3× 317 0.8× 423 1.1× 31 0.5× 9 809
John McKolanis United States 12 682 0.7× 558 0.9× 168 0.4× 391 1.0× 57 0.9× 32 1.1k
Stefanie Loeser Austria 7 479 0.5× 301 0.5× 117 0.3× 341 0.9× 23 0.4× 7 813
Judy Browning Australia 15 678 0.7× 429 0.7× 68 0.2× 392 1.0× 49 0.8× 18 925
Clay Davis United States 9 244 0.3× 330 0.5× 294 0.7× 281 0.7× 68 1.1× 11 744
J R Corvalán United Kingdom 10 227 0.2× 334 0.5× 427 1.0× 342 0.9× 33 0.5× 17 789
Kenneth F. May United States 12 899 1.0× 667 1.1× 100 0.2× 168 0.4× 47 0.8× 16 1.1k

Countries citing papers authored by Catherine E. Storrer

Since Specialization
Citations

This map shows the geographic impact of Catherine E. Storrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine E. Storrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine E. Storrer more than expected).

Fields of papers citing papers by Catherine E. Storrer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine E. Storrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine E. Storrer. The network helps show where Catherine E. Storrer may publish in the future.

Co-authorship network of co-authors of Catherine E. Storrer

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine E. Storrer. A scholar is included among the top collaborators of Catherine E. Storrer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine E. Storrer. Catherine E. Storrer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Peoples, George E., Jarrod P. Holmes, Matthew T. Hueman, et al.. (2008). Combined Clinical Trial Results of a HER2/neu(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clinical Cancer Research. 14(3). 797–803. 140 indexed citations
3.
Dehqanzada, Zia A., Catherine E. Storrer, Matthew T. Hueman, et al.. (2007). Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology. Oncology Reports. 17(3). 687–94. 61 indexed citations
4.
Holmes, Jarrod P., Asna Amin, Catherine E. Storrer, et al.. (2007). Clinical and immunologic effects of a HER2/neu (E75) peptide vaccine booster in previously vaccinated breast cancer patients. Journal of Clinical Oncology. 25(18_suppl). 3014–3014. 3 indexed citations
5.
Mittendorf, Elizabeth A., Jennifer M. Gurney, Catherine E. Storrer, et al.. (2006). Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery. 139(3). 407–418. 35 indexed citations
6.
Mittendorf, Elizabeth A., Catherine E. Storrer, Katie Harris, et al.. (2006). Evaluation of the HER2/neu‐derived peptide GP2 for use in a peptide‐based breast cancer vaccine trial. Cancer. 106(11). 2309–2317. 65 indexed citations
7.
Hueman, Matthew T., Alexander Stojadinovic, Catherine E. Storrer, et al.. (2006). Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★. Breast Cancer Research and Treatment. 98(1). 17–29. 40 indexed citations
8.
Mittendorf, Elizabeth A., Catherine E. Storrer, Craig D. Shriver, Sathibalan Ponniah, & George E. Peoples. (2006). Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer. Annals of Surgical Oncology. 13(8). 1085–1098. 62 indexed citations
9.
Hueman, Matthew T., Catherine E. Storrer, Katie Harris, et al.. (2006). Immunological monitoring of regulatory T cells by flow cytometry in a novel HLA Class II HER2/neu peptide vaccine clinical trial in breast cancer patients. Journal of the American College of Surgeons. 203(3). S79–S79. 1 indexed citations
10.
Mittendorf, EA, Catherine E. Storrer, Katie Harris, et al.. (2006). Early results of a phase I clinical trial of an Ii-Key/Her2/neu MHC class II peptide-based vaccine in breast cancer patients. Journal of Clinical Oncology. 24(18_suppl). 2532–2532. 3 indexed citations
11.
Hueman, Matthew T., Alexander Stojadinovic, Catherine E. Storrer, et al.. (2006). Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunology Immunotherapy. 56(2). 135–146. 34 indexed citations
12.
Storrer, Catherine E., Katie Harris, Zia A. Dehqanzada, et al.. (2006). Early results of a phase I clinical trial of an Ii-Key/HER2/neu MHC Class II peptide-based vaccine in breast cancer patients. Journal of the American College of Surgeons. 203(3). S81–S81. 1 indexed citations
13.
Mittendorf, Elizabeth A., Catherine E. Storrer, Craig D. Shriver, Sathibalan Ponniah, & George E. Peoples. (2005). Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Research and Treatment. 92(1). 85–93. 41 indexed citations
14.
Peoples, George E., Jennifer M. Gurney, Catherine E. Storrer, et al.. (2005). Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients. Journal of Clinical Oncology. 23(30). 7536–7545. 181 indexed citations
15.
Gurney, Jennifer M., Matthew T. Hueman, Michael Woll, et al.. (2005). Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. Journal of Clinical Oncology. 23(16_suppl). 2575–2575. 160 indexed citations
16.
Woll, Michael, Christine M. Fisher, Jennifer M. Gurney, et al.. (2004). Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients. Journal of Clinical Immunology. 24(4). 449–461. 32 indexed citations
17.
18.
Mittendorf, Elizabeth A., et al.. (2004). Evaluation of the Cd107a cytotoxicity assay for the detection of cytolytic CD8 cells recognizing Her2/neu vaccine peptides. Journal of Surgical Research. 121(2). 327–327. 1 indexed citations
19.
Luzina, Irina G., Sergei P. Atamas, Catherine E. Storrer, et al.. (2001). Spontaneous formation of germinal centers in autoimmune mice. Journal of Leukocyte Biology. 70(4). 578–584. 148 indexed citations
20.
Handwerger, Barry S., et al.. (1999). Further Characterization of the Autoantibody Response of Palmerston North Mice. Journal of Clinical Immunology. 19(1). 45–57. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katharine M. Bendt Breakdown of academic impact, for papers by M.J. Troychak Breakdown of academic impact, for papers by Gijs Verheijden Breakdown of academic impact, for papers by Louise W. Treffers Breakdown of academic impact, for papers by John McKolanis Breakdown of academic impact, for papers by Stefanie Loeser Breakdown of academic impact, for papers by Judy Browning Breakdown of academic impact, for papers by Clay Davis Breakdown of academic impact, for papers by J R Corvalán Breakdown of academic impact, for papers by Kenneth F. May
Rankless by CCL
2026